Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Drug: Sevabertinib in Advanced HER2-Mutant NSCLC
Sevabertinib showed significant activity in patients with HER2-mutant NSCLC, achieving high response rates across different cohorts. The drug demonstrated a favorable response even
New Drug: Sacituzumab Tirumotecan for EGFR-Mutated Advanced NSCLC
Sacituzumab tirumotecan significantly improved progression-free survival and overall survival in patients with EGFR-mutated NSCLC resistant to previous EGFR-TKI therapy compared to
New Reference: Rucaparib for Maintenance in Advanced Ovarian Cancer
The ATHENA-MONO study demonstrated significant improvement in progression-free survival with rucaparib as maintenance therapy for newly diagnosed advanced ovarian cancer. The hazar
New Indication: Trastuzumab Deruxtecan with Pertuzumab for First-Line Metastatic Her2-Positive Breast Cancer
Trastuzumab deruxtecan plus pertuzumab demonstrated a significantly lower risk of progression or death compared to the THP regimen as a first-line treatment for HER2-positive metas
New Indication: Neoadjuvant Trastuzumab Deruxtecan For High-Risk her2-Positive Breast Cancer
This phase 3 trial showed that T-DXd-THP significantly improved the pathological complete response rate compared with ddAC-THP in high-risk HER2-positive early breast cancer, with
New Reference: 3 vs 6 Cycles of Chemotherapy for Advanced Urothelial Carcinoma
The phase II DISCUS trial investigated the effectiveness of 3 versus 6 cycles of platinum-based chemotherapy followed by avelumab maintenance in advanced urothelial cancer patients
New Reference: Panitumumab for Ras/Raf WT Metastatic Colorectal Cancer After Anti-EGFR Therapy
The study evaluated sequencing of panitumumab and regorafenib in chemorefractory colorectal cancer, showing no difference in overall survival but superior response rates and diseas
New Drug: Ziftomenib for Relapsed/Refractory NPM1-Mutated AML
Ziftomenib monotherapy led to a complete remission rate of 22% with a median overall survival of 6.6 months among relapsed/refractory NPM1-mutated AML patients. It was well tolerat
New Drug: Izalontamab Brengitecan for Metastatic Nasopharyngeal Carcinoma
Izalontamab brengitecan significantly improved objective response rate and progression-free survival compared to chemotherapy in heavily pretreated nasopharyngeal carcinoma patient
